Horizant gabapentin enacarbil: Phase IIb data

Top-line data from a 30-week, double-blind, dose-ranging, North American Phase IIb trial in 526 patients showed that gabapentin enacarbil missed the primary endpoint of significantly reducing the number of migraine headache days during the last 4 weeks of the treatment maintenance period compared to the number of headache days during the last 4 weeks of the baseline period prior to beginning treatment vs. placebo. The partners said the failure could be due to an unexpectedly high placebo response rate. The most common adverse event was dizziness. Patients received 1,200; 1,800; 2,400; or 3,000 mg/day gabapentin enacarbil or placebo. ...